WHAT GOT US

THINKING

The cost associated with in-center dialysis treatment continues to rise, but only about 1 in 8 U.S. dialysis patients receives home dialysis.

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

 

​

And despite its potential for improved health outcomes and quality of life, as well as decreased cost of care...

 

 

 

 

 

 

 

 

 

​

​

​

​

​

​

​

​

 

only about 1 in 7 of these home dialysis patients receives home hemodialysis (HHD).

THEN

[RE]THINKING

We focused on the high patient burden of home hemodialysis (HHD), with the goal of reducing the barriers associated with HHD machines in order to promote consistent and sustained treatment in the home and wherever the patient travels. These barriers include:

​

• Limited range of prescriptions some machines can deliver.

• Long patient learning curve requiring extensive training.

• Low patient confidence and high intimidation factor.

• Extensive time and effort to initiate treatment.

• Many manual steps for set-up and treatment.

• Large, heavy, cumbersome machines.

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

AND NOW

[RE]DEFINING

We are investigating key aspects of home hemodialysis delivery.

​

​

SIMPLE

Time and effort required for training, machine set-up and operation to reduce patient intimidation and burnout.*

​

SMART

Degree of automated vs. user-initiated process steps during set-up and use to reduce the potential for error associated with manual operations.*

FLEXIBLE

Range of hemodialysis modalities to potentially expand the population of patients that may benefit from home hemodialysis.*

PORTABLE

Footprint and ease of transporting to reduce space requirements in the home and make travel more convenient, with the goal of improving patient quality of life.*

​

​

​

*The performance characteristics of this product have not been established. This product is not yet available for use in the EU or US and is pending CE Mark and submission and clearance by the United States Food and Drug Administration. All performance claims listed are project goals only.

​

​

​